{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:34Z","timestamp":1789593754411,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01456-4","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:46:01Z","timestamp":1773330361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-9844","authenticated-orcid":false,"given":"Wan-Hsuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-2285","authenticated-orcid":false,"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-2472","authenticated-orcid":false,"given":"Feng-Ming","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yen","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4571-3328","authenticated-orcid":false,"given":"Yu-Sung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Hsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-9000","authenticated-orcid":false,"given":"Yuan-Yeh","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-9445","authenticated-orcid":false,"given":"Chi-Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-8045","authenticated-orcid":false,"given":"Chia-Lang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Tsu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-7579","authenticated-orcid":false,"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-698X","authenticated-orcid":false,"given":"Wen-Chien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"1456_CR1","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/curroncol31040148","volume":"31","author":"D Karel","year":"2024","unstructured":"Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic neoplasms (MDS): the current and future treatment landscape. Curr Oncol. 2024;31:1971\u201393.","journal-title":"Curr Oncol"},{"key":"1456_CR2","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJMra0902908","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872\u201385.","journal-title":"N Engl J Med"},{"key":"1456_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328:872\u201380.","journal-title":"JAMA"},{"key":"1456_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1456_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1456_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garc\u00eda-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496\u2013506.","journal-title":"N Engl J Med"},{"key":"1456_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1456_CR8","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/j.clml.2024.12.021","volume":"25","author":"WH Lee","year":"2025","unstructured":"Lee WH, Lin CC, Tsai XC, Tien FM, Lo MY, Kuo YY, et al. Epidemiology, treatment outcomes, and prognosis of myelodysplastic syndromes\/neoplasms in Taiwan: real-world insights and trends. Clin Lymphoma Myeloma Leuk. 2025;25:e336\u2013e47.e14.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1456_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01339-0","volume":"15","author":"H Gill","year":"2025","unstructured":"Gill H, Yim R, Lee P, Tsai XC, Li VWK, Leung GMK, et al. A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia. Blood Cancer J. 2025;15:128.","journal-title":"Blood Cancer J"},{"key":"1456_CR10","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","volume":"33","author":"D Singhal","year":"2019","unstructured":"Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia. 2019;33:2842\u201353.","journal-title":"Leukemia"},{"key":"1456_CR11","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","volume":"105","author":"T Kuzmanovic","year":"2020","unstructured":"Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, et al. Genomics of therapy-related myeloid neoplasms. Haematologica. 2020;105:e98\u2013e101.","journal-title":"Haematologica"},{"key":"1456_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01031-9","volume":"14","author":"WH Lee","year":"2024","unstructured":"Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Tseng MH, et al. Comparison of the 2022 World Health Organization classification and international consensus classification in myelodysplastic syndromes\/neoplasms. Blood Cancer J. 2024;14:57.","journal-title":"Blood Cancer J"},{"key":"1456_CR13","unstructured":"International Standing Committee on Human Cytogenomic Nomenclature M-JJHRJMSSKG. ISCN 2020, an International System for Human Cytogenomic Nomenclature 2020: recommendations of the International Standing Committee on Human Cytogenomic Nomenclature, including revised sequence-based cytogenomic nomenclature developed in collaboration with the Human Genome Variation Society (HGVS) Sequence Variant Description Working Group, 2020."},{"key":"1456_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00894-8","volume":"13","author":"WH Lee","year":"2023","unstructured":"Lee WH, Tsai MT, Tsai CH, Tien FM, Lo MY, Tseng MH, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer J. 2023;13:120.","journal-title":"Blood Cancer J"},{"key":"1456_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29\u201341.","journal-title":"Blood"},{"key":"1456_CR16","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/ajh.26734","volume":"97","author":"WH Lee","year":"2022","unstructured":"Lee WH, Lin CC, Tsai CH, Tseng MH, Kuo YY, Liu MC, et al. Effect of mutation allele frequency on the risk stratification of myelodysplastic syndrome patients. Am J Hematol. 2022;97:1589\u201398.","journal-title":"Am J Hematol"},{"key":"1456_CR17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"CH Tsai","year":"2021","unstructured":"Tsai CH, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5:2456\u201366.","journal-title":"Blood Adv"},{"key":"1456_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ajh.26799","volume":"98","author":"WH Lee","year":"2023","unstructured":"Lee WH, Lin CC, Tsai CH, Tien FM, Lo MY, Ni SC, et al. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome\/acute myeloid leukemia based on the 2022 International Consensus Classification. Am J Hematol. 2023;98:398\u2013407.","journal-title":"Am J Hematol"},{"key":"1456_CR19","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/bloodadvances.2023011512","volume":"8","author":"CY Yao","year":"2024","unstructured":"Yao CY, Lin CC, Wang YH, Kao CJ, Tsai CH, Hou HA, et al. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes. Blood Adv. 2024;8:2442\u201354.","journal-title":"Blood Adv"},{"key":"1456_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/21925682211005732","volume":"13","author":"BW Zheng","year":"2023","unstructured":"Zheng BW, Huang W, Liu FS, Zhang TL, Wang XB, Li J, et al. Clinicopathological and prognostic characteristics in spinal chondroblastomas: a pooled analysis of individual patient data from a single institute and 27 studies. Global Spine J. 2023;13:713\u201323.","journal-title":"Global Spine J"},{"key":"1456_CR21","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1002\/sim.5384","volume":"31","author":"E Laska","year":"2012","unstructured":"Laska E, Meisner M, Wanderling J. A maximally selected test of symmetry about zero. Stat Med. 2012;31:3178\u201391.","journal-title":"Stat Med"},{"key":"1456_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","volume":"54","author":"EW Steyerberg","year":"2001","unstructured":"Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774\u201381.","journal-title":"J Clin Epidemiol"},{"key":"1456_CR23","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilst\u00f6cker M, N\u00f6sslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385\u201395.","journal-title":"Blood"},{"key":"1456_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0061-z","volume":"8","author":"J Schanz","year":"2018","unstructured":"Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, et al. Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer J. 2018;8:28.","journal-title":"Blood Cancer J"},{"key":"1456_CR25","first-page":"1168","volume":"90","author":"F Sol\u00e9","year":"2005","unstructured":"Sol\u00e9 F, Lu\u00f1o E, Sanzo C, Espinet B, Sanz GF, Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90:1168\u201378.","journal-title":"Haematologica"},{"key":"1456_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09864-9","volume":"12","author":"N Maurya","year":"2022","unstructured":"Maurya N, Mohanty P, Dhangar S, Panchal P, Jijina F, Mathan SLP, et al. Comprehensive analysis of genetic factors predicting overall survival in myelodysplastic syndromes. Sci Rep. 2022;12:5925.","journal-title":"Sci Rep"},{"key":"1456_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/hon.3109","volume":"41","author":"WH Lee","year":"2023","unstructured":"Lee WH, Lin CC, Wang YH, Yao CY, Kuo YY, Tseng MH, et al. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. Hematol Oncol. 2023;41:463\u201373.","journal-title":"Hematol Oncol"},{"key":"1456_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05243-6","volume":"12","author":"E Schaafsma","year":"2022","unstructured":"Schaafsma E, Takacs EM, Kaur S, Cheng C, Kurokawa M. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature. Sci Rep. 2022;12:1317.","journal-title":"Sci Rep"},{"key":"1456_CR29","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552\u201361.","journal-title":"N Engl J Med"},{"key":"1456_CR30","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/bloodadvances.2023010156","volume":"7","author":"HJ Abel","year":"2023","unstructured":"Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, et al. Genomic landscape of TP53-mutated myeloid malignancies. Blood Adv. 2023;7:4586\u201398.","journal-title":"Blood Adv"},{"key":"1456_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"1456_CR32","doi-asserted-by":"crossref","unstructured":"Voskarides K, Giannopoulou N. The role of TP53 in adaptation and evolution. Cells. 2023;12:512.","DOI":"10.3390\/cells12030512"},{"key":"1456_CR33","first-page":"3533","volume":"109","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, et al. Prognostic impact of \u201cmulti-hit\u201d versus \u201csingle-hit\u201d TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024;109:3533\u201342.","journal-title":"Haematologica"},{"key":"1456_CR34","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1456_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0275-8","volume":"10","author":"A Ravindran","year":"2020","unstructured":"Ravindran A, He R, Ketterling RP, Jawad MD, Chen D, Oliveira JL, et al. The significance of genetic mutations and their prognostic impact on patients with an incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer J. 2020;10:7.","journal-title":"Blood Cancer J"},{"key":"1456_CR36","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1002\/ajh.27170","volume":"99","author":"W Wang","year":"2024","unstructured":"Wang W, Zhang Y, Yang W, Han Y, Jiang L, Liu X, et al. Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact. Am J Hematol. 2024;99:E51\u2013e4.","journal-title":"Am J Hematol"},{"key":"1456_CR37","doi-asserted-by":"publisher","first-page":"E420","DOI":"10.1002\/ajh.26325","volume":"96","author":"SA Wang","year":"2021","unstructured":"Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, et al. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021;96:E420\u2013e3.","journal-title":"Am J Hematol"},{"key":"1456_CR38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"1456_CR39","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","volume":"23","author":"L Malcovati","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594\u2013603.","journal-title":"J Clin Oncol"},{"key":"1456_CR40","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","volume":"109","author":"P Armand","year":"2007","unstructured":"Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586\u20138.","journal-title":"Blood"},{"key":"1456_CR41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","volume":"27","author":"MG Della Porta","year":"2009","unstructured":"Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754\u201362.","journal-title":"J Clin Oncol"},{"key":"1456_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.clml.2020.01.003","volume":"20","author":"M Melody","year":"2020","unstructured":"Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, et al. Decoding bone marrow fibrosis in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2020;20:324\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1456_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3343\/alm.2022.42.3.299","volume":"42","author":"AG Jain","year":"2022","unstructured":"Jain AG, Zhang L, Bennett JM, Komrokji R. Myelodysplastic syndromes with bone marrow fibrosis: an update. Ann Lab Med. 2022;42:299\u2013305.","journal-title":"Ann Lab Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01456-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:01:35Z","timestamp":1773993695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01456-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01456-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}